Table of Contents Chapter 1 Overview of Bioengineered Protein Drugs 1.1 Definition of Bioengineered Protein Drugs in This Report 1.2 Commercial Types of Bioengineered Protein Drugs 1.2.1 Therapeutic Proteins 1.2.2 Monoclonal Antibodies 1.2.3 Vaccines 1.3 Downstream Application of Bioengineered Protein Drugs 1.3.1 Diabetes and Hormonal Disorders 1.3.2 Genetic and Fertility Disorders 1.3.3 Cancers 1.3.4 Organ Transplants 1.3.5 Others 1.4 Development History of Bioengineered Protein Drugs 1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023 1.5.1 Global Bioengineered Protein Drugs Market Status and Trend 2013-2023 1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Bioengineered Protein Drugs 2013-2017 2.2 Sales Market of Bioengineered Protein Drugs by Regions 2.2.1 Sales Volume of Bioengineered Protein Drugs by Regions 2.2.2 Sales Value of Bioengineered Protein Drugs by Regions 2.3 Production Market of Bioengineered Protein Drugs by Regions 2.4 Global Market Forecast of Bioengineered Protein Drugs 2018-2023 2.4.1 Global Market Forecast of Bioengineered Protein Drugs 2018-2023 2.4.2 Market Forecast of Bioengineered Protein Drugs by Regions 2018-2023 Chapter 3 Global Market Status and Forecast by Types 3.1 Sales Volume of Bioengineered Protein Drugs by Types 3.2 Sales Value of Bioengineered Protein Drugs by Types 3.3 Market Forecast of Bioengineered Protein Drugs by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Global Sales Volume of Bioengineered Protein Drugs by Downstream Industry 4.2 Global Market Forecast of Bioengineered Protein Drugs by Downstream Industry Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry 5.1 North America Bioengineered Protein Drugs Market Status by Countries 5.1.1 North America Bioengineered Protein Drugs Sales by Countries (2013-2017) 5.1.2 North America Bioengineered Protein Drugs Revenue by Countries (2013-2017) 5.1.3 United States Bioengineered Protein Drugs Market Status (2013-2017) 5.1.4 Canada Bioengineered Protein Drugs Market Status (2013-2017) 5.1.5 Mexico Bioengineered Protein Drugs Market Status (2013-2017) 5.2 North America Bioengineered Protein Drugs Market Status by Manufacturers 5.3 North America Bioengineered Protein Drugs Market Status by Type (2013-2017) 5.3.1 North America Bioengineered Protein Drugs Sales by Type (2013-2017) 5.3.2 North America Bioengineered Protein Drugs Revenue by Type (2013-2017) 5.4 North America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017) Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry 6.1 Europe Bioengineered Protein Drugs Market Status by Countries 6.1.1 Europe Bioengineered Protein Drugs Sales by Countries (2013-2017) 6.1.2 Europe Bioengineered Protein Drugs Revenue by Countries (2013-2017) 6.1.3 Germany Bioengineered Protein Drugs Market Status (2013-2017) 6.1.4 UK Bioengineered Protein Drugs Market Status (2013-2017) 6.1.5 France Bioengineered Protein Drugs Market Status (2013-2017) 6.1.6 Italy Bioengineered Protein Drugs Market Status (2013-2017) 6.1.7 Russia Bioengineered Protein Drugs Market Status (2013-2017) 6.1.8 Spain Bioengineered Protein Drugs Market Status (2013-2017) 6.1.9 Benelux Bioengineered Protein Drugs Market Status (2013-2017) 6.2 Europe Bioengineered Protein Drugs Market Status by Manufacturers 6.3 Europe Bioengineered Protein Drugs Market Status by Type (2013-2017) 6.3.1 Europe Bioengineered Protein Drugs Sales by Type (2013-2017) 6.3.2 Europe Bioengineered Protein Drugs Revenue by Type (2013-2017) 6.4 Europe Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017) Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry 7.1 Asia Pacific Bioengineered Protein Drugs Market Status by Countries 7.1.1 Asia Pacific Bioengineered Protein Drugs Sales by Countries (2013-2017) 7.1.2 Asia Pacific Bioengineered Protein Drugs Revenue by Countries (2013-2017) 7.1.3 China Bioengineered Protein Drugs Market Status (2013-2017) 7.1.4 Japan Bioengineered Protein Drugs Market Status (2013-2017) 7.1.5 India Bioengineered Protein Drugs Market Status (2013-2017) 7.1.6 Southeast Asia Bioengineered Protein Drugs Market Status (2013-2017) 7.1.7 Australia Bioengineered Protein Drugs Market Status (2013-2017) 7.2 Asia Pacific Bioengineered Protein Drugs Market Status by Manufacturers 7.3 Asia Pacific Bioengineered Protein Drugs Market Status by Type (2013-2017) 7.3.1 Asia Pacific Bioengineered Protein Drugs Sales by Type (2013-2017) 7.3.2 Asia Pacific Bioengineered Protein Drugs Revenue by Type (2013-2017) 7.4 Asia Pacific Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017) Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry 8.1 Latin America Bioengineered Protein Drugs Market Status by Countries 8.1.1 Latin America Bioengineered Protein Drugs Sales by Countries (2013-2017) 8.1.2 Latin America Bioengineered Protein Drugs Revenue by Countries (2013-2017) 8.1.3 Brazil Bioengineered Protein Drugs Market Status (2013-2017) 8.1.4 Argentina Bioengineered Protein Drugs Market Status (2013-2017) 8.1.5 Colombia Bioengineered Protein Drugs Market Status (2013-2017) 8.2 Latin America Bioengineered Protein Drugs Market Status by Manufacturers 8.3 Latin America Bioengineered Protein Drugs Market Status by Type (2013-2017) 8.3.1 Latin America Bioengineered Protein Drugs Sales by Type (2013-2017) 8.3.2 Latin America Bioengineered Protein Drugs Revenue by Type (2013-2017) 8.4 Latin America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017) Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry 9.1 Middle East and Africa Bioengineered Protein Drugs Market Status by Countries 9.1.1 Middle East and Africa Bioengineered Protein Drugs Sales by Countries (2013-2017) 9.1.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Countries (2013-2017) 9.1.3 Middle East Bioengineered Protein Drugs Market Status (2013-2017) 9.1.4 Africa Bioengineered Protein Drugs Market Status (2013-2017) 9.2 Middle East and Africa Bioengineered Protein Drugs Market Status by Manufacturers 9.3 Middle East and Africa Bioengineered Protein Drugs Market Status by Type (2013-2017) 9.3.1 Middle East and Africa Bioengineered Protein Drugs Sales by Type (2013-2017) 9.3.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Type (2013-2017) 9.4 Middle East and Africa Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017) Chapter 10 Market Driving Factor Analysis of Bioengineered Protein Drugs 10.1 Global Economy Situation and Trend Overview 10.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview Chapter 11 Bioengineered Protein Drugs Market Competition Status by Major Manufacturers 11.1 Production Volume of Bioengineered Protein Drugs by Major Manufacturers 11.2 Production Value of Bioengineered Protein Drugs by Major Manufacturers 11.3 Basic Information of Bioengineered Protein Drugs by Major Manufacturers 11.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Manufacturer 11.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Manufacturer 11.4 Market Competition News and Trend 11.4.1 Merger, Consolidation or Acquisition News 11.4.2 Investment or Disinvestment News 11.4.3 New Product Development and Launch Chapter 12 Bioengineered Protein Drugs Major Manufacturers Introduction and Market Data 12.1 Abbott Laboratories 12.1.1 Company profile 12.1.2 Representative Bioengineered Protein Drugs Product 12.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories 12.2 F. Hoffmann-La Roche Ltd 12.2.1 Company profile 12.2.2 Representative Bioengineered Protein Drugs Product 12.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 12.3 Amgen, Inc. 12.3.1 Company profile 12.3.2 Representative Bioengineered Protein Drugs Product 12.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc. 12.4 Bayer AG 12.4.1 Company profile 12.4.2 Representative Bioengineered Protein Drugs Product 12.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG 12.5 Merck & Co., Inc. 12.5.1 Company profile 12.5.2 Representative Bioengineered Protein Drugs Product 12.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 12.6 Dr. Reddy's Laboratories Ltd. 12.6.1 Company profile 12.6.2 Representative Bioengineered Protein Drugs Product 12.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd. 12.7 Biocon Ltd. 12.7.1 Company profile 12.7.2 Representative Bioengineered Protein Drugs Product 12.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd. 12.8 Eli Lilly and Company 12.8.1 Company profile 12.8.2 Representative Bioengineered Protein Drugs Product 12.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 12.9 Sanofi 12.9.1 Company profile 12.9.2 Representative Bioengineered Protein Drugs Product 12.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi 12.10 GlaxoSmithKline plc 12.10.1 Company profile 12.10.2 Representative Bioengineered Protein Drugs Product 12.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc 12.11 Johnson & Johnson 12.11.1 Company profile 12.11.2 Representative Bioengineered Protein Drugs Product 12.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson 12.12 JanssenNovartis AG 12.12.1 Company profile 12.12.2 Representative Bioengineered Protein Drugs Product 12.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG 12.13 Panacea Biotec 12.13.1 Company profile 12.13.2 Representative Bioengineered Protein Drugs Product 12.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec 12.14 ProBioGen AG 12.14.1 Company profile 12.14.2 Representative Bioengineered Protein Drugs Product 12.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG Chapter 13 Upstream and Downstream Market Analysis of Bioengineered Protein Drugs 13.1 Industry Chain of Bioengineered Protein Drugs 13.2 Upstream Market and Representative Companies Analysis 13.3 Downstream Market and Representative Companies Analysis Chapter 14 Cost and Gross Margin Analysis of Bioengineered Protein Drugs 14.1 Cost Structure Analysis of Bioengineered Protein Drugs 14.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs 14.3 Labor Cost Analysis of Bioengineered Protein Drugs 14.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs Chapter 15 Report Conclusion Chapter 16 Research Methodology and Reference 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Reference

List of Tables Table Advantage and Disadvantage of Therapeutic Proteins Table Advantage and Disadvantage of Monoclonal Antibodies Table Advantage and Disadvantage of Vaccines Table Sales Volume of Bioengineered Protein Drugs by Regions 2013-2017 Table Sales Value of Bioengineered Protein Drugs by Regions 2013-2017 Table Production Volume of Bioengineered Protein Drugs by Regions 2013-2017 Table Global Sales Volume of Bioengineered Protein Drugs by Regions 2018-2023 Table Global Sales Value of Bioengineered Protein Drugs by Regions 2018-2023 Table Global Production Volume of Bioengineered Protein Drugs by Regions 2018-2023 Table Sales Volume of Bioengineered Protein Drugs by Types 2013-2017 Table Sales Value of Bioengineered Protein Drugs by Types 2013-2017 Table Sales Volume Forecast of Bioengineered Protein Drugs by Types 2018-2023 Table Sales Value Forecast of Bioengineered Protein Drugs by Types 2018-2023 Table Sales Volume of Bioengineered Protein Drugs by Downstream Industry 2013-2017 Table Sales Volume Forecast of Bioengineered Protein Drugs by Downstream Industry 2018-2023 Table North America Bioengineered Protein Drugs Sales by Countries (2013-2017) Table North America Bioengineered Protein Drugs Sales Share by Countries (2013-2017) Table North America Bioengineered Protein Drugs Revenue by Countries (2013-2017) Table North America Bioengineered Protein Drugs Revenue Market Share by Countries (2013-2017) Table North America Bioengineered Protein Drugs Sales by Type (2013-2017) Table North America Bioengineered Protein Drugs Sales Share by Type (2013-2017) Table North America Bioengineered Protein Drugs Revenue by Type (2013-2017) Table North America Bioengineered Protein Drugs Revenue Share by Type (2013-2017) Table North America Bioengineered Protein Drugs Sales by Downstream Industry (2013-2017) Table North America Bioengineered Protein Drugs Sales Share by Downstream Industry (2013-2017) Table Europe Bioengineered Protein Drugs Sales by Countries (2013-2017) Table Europe Bioengineered Protein Drugs Sales Share by Countries (2013-2017) Table Europe Bioengineered Protein Drugs Revenue by Countries (2013-2017) Table Europe Bioengineered Protein Drugs Revenue Market Share by Countries (2013-2017) Table Europe Bioengineered Protein Drugs Sales by Type (2013-2017) Table Europe Bioengineered Protein Drugs Sales Share by Type (2013-2017) Table Europe Bioengineered Protein Drugs Revenue by Type (2013-2017) Table Europe Bioengineered Protein Drugs Revenue Share by Type (2013-2017) Table Europe Bioengineered Protein Drugs Sales by Downstream Industry (2013-2017) Table Europe Bioengineered Protein Drugs Sales Share by Downstream Industry (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales by Countries (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales Share by Countries (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Revenue by Countries (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Revenue Market Share by Countries (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales by Type (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales Share by Type (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Revenue by Type (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Revenue Share by Type (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales by Downstream Industry (2013-2017) Table Asia Pacific Bioengineered Protein Drugs Sales Share by Downstream Industry (2013-2017) Table Latin America Bioengineered Protein Drugs Sales by Countries (2013-2017) Table Latin America Bioengineered Protein Drugs Sales Share by Countries (2013-2017) Table Latin America Bioengineered Protein Drugs Revenue by Countries (2013-2017) Table Latin America Bioengineered Protein Drugs Revenue Market Share by Countries (2013-2017) Table Latin America Bioengineered Protein Drugs Sales by Type (2013-2017) Table Latin America Bioengineered Protein Drugs Sales Share by Type (2013-2017) Table Latin America Bioengineered Protein Drugs Revenue by Type (2013-2017) Table Latin America Bioengineered Protein Drugs Revenue Share by Type (2013-2017) Table Latin America Bioengineered Protein Drugs Sales by Downstream Industry (2013-2017) Table Latin America Bioengineered Protein Drugs Sales Share by Downstream Industry (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales by Regions (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales Share by Regions (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Revenue by Regions (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Revenue Market Share by Regions (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales by Type (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales Share by Type (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Revenue by Type (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Revenue Share by Type (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales by Downstream Industry (2013-2017) Table Middle East and Africa Bioengineered Protein Drugs Sales Share by Downstream Industry (2013-2017) Table Production Volume of Bioengineered Protein Drugs by Major Manufacturers 2013-2017 Table Production Value of Bioengineered Protein Drugs by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Bioengineered Protein Drugs Major Manufacturer Table Employees and Revenue Level of Bioengineered Protein Drugs Major Manufacturer Table Representative Bioengineered Protein Drugs Product One of Abbott Laboratories Table Representative Bioengineered Protein Drugs Product Two of Abbott Laboratories Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories 2013-2017 Table Representative Bioengineered Protein Drugs Product One of F. Hoffmann-La Roche Ltd Table Representative Bioengineered Protein Drugs Product Two of F. Hoffmann-La Roche Ltd Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Amgen, Inc. Table Representative Bioengineered Protein Drugs Product Two of Amgen, Inc. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Bayer AG Table Representative Bioengineered Protein Drugs Product Two of Bayer AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Merck & Co., Inc. Table Representative Bioengineered Protein Drugs Product Two of Merck & Co., Inc. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Dr. Reddy's Laboratories Ltd. Table Representative Bioengineered Protein Drugs Product Two of Dr. Reddy's Laboratories Ltd. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Biocon Ltd. Table Representative Bioengineered Protein Drugs Product Two of Biocon Ltd. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Eli Lilly and Company Table Representative Bioengineered Protein Drugs Product Two of Eli Lilly and Company Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Sanofi Table Representative Bioengineered Protein Drugs Product Two of Sanofi Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi 2013-2017 Table Representative Bioengineered Protein Drugs Product One of GlaxoSmithKline plc Table Representative Bioengineered Protein Drugs Product Two of GlaxoSmithKline plc Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Johnson & Johnson Table Representative Bioengineered Protein Drugs Product Two of Johnson & Johnson Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017 Table Representative Bioengineered Protein Drugs Product One of JanssenNovartis AG Table Representative Bioengineered Protein Drugs Product Two of JanssenNovartis AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Panacea Biotec Table Representative Bioengineered Protein Drugs Product Two of Panacea Biotec Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec 2013-2017 Table Representative Bioengineered Protein Drugs Product One of ProBioGen AG Table Representative Bioengineered Protein Drugs Product Two of ProBioGen AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG 2013-2017